Cooper Companies (COO)
Market Price (11/6/2026): $63.49 | Market Cap: $12.1 BilInvestor Relations Sector: Health Care | Industry: Health Care Supplies
Cooper Companies (COO)
Market Price (11/6/2026): $63.49Market Cap: $12.1 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16% Attractive yieldFCF Yield is 5.5% Low stock price volatilityVol 12M is 33% Megatrend and thematic driversMegatrends include Precision Medicine, Biotechnology & Genomics, and Health & Wellness Innovations. Themes include Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -74%, 3Y Excs Rtn is -102% | Key risksCOO key risks include [1] challenges from its extensive international operations, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16% |
| Attractive yieldFCF Yield is 5.5% |
| Low stock price volatilityVol 12M is 33% |
| Megatrend and thematic driversMegatrends include Precision Medicine, Biotechnology & Genomics, and Health & Wellness Innovations. Themes include Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -74%, 3Y Excs Rtn is -102% |
| Key risksCOO key risks include [1] challenges from its extensive international operations, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Cooper Companies (COO) stock has lost about 10% since 7/31/2026 because of the following key factors:
1. CooperCompanies lowered its fiscal Q4 2026 and full-year 2026 financial guidance, primarily due to weakness in its CooperVision segment. The company reported fiscal Q3 2026 (ended July 31, 2026) revenue of $1.066 billion, which missed analyst expectations of $1.10 billion. Notably, CooperVision's revenue was flat in fiscal Q3 2026 due to a reduction in U.S. channel inventory, a issue expected to continue impacting fiscal Q4. Consequently, on September 9, 2026, CooperCompanies reduced its fiscal Q4 2026 total revenue guidance to $1.057 - $1.080 billion (0% to 2% organic growth) and its full-year fiscal 2026 revenue guidance to $4.229 - $4.252 billion (2% to 3% organic growth). Non-GAAP diluted EPS guidance was also lowered for fiscal Q4 2026 to $1.05 - $1.09 and for the full fiscal year 2026 to $4.51 - $4.55. This guidance cut contributed to a 15% stock plunge on September 10, 2026.
2. The company unexpectedly decided to retain its CooperSurgical business following a strategic review. After undertaking a strategic review process since December 2025, CooperCompanies announced on September 9, 2026, that its board decided against the potential sale of its CooperSurgical division. The board concluded that retaining the business was the best course for maximizing shareholder value at the time. This decision surprised analysts who had anticipated a sale, leading several firms, including William Blair, BofA Securities, Wells Fargo, and Piper Sandler, to downgrade the stock and reduce their price targets.
Show more
Cooper Companies (COO) stock has lost about 10% since 7/31/2026 because of the following key factors:
1. CooperCompanies lowered its fiscal Q4 2026 and full-year 2026 financial guidance, primarily due to weakness in its CooperVision segment. The company reported fiscal Q3 2026 (ended July 31, 2026) revenue of $1.066 billion, which missed analyst expectations of $1.10 billion. Notably, CooperVision's revenue was flat in fiscal Q3 2026 due to a reduction in U.S. channel inventory, a issue expected to continue impacting fiscal Q4. Consequently, on September 9, 2026, CooperCompanies reduced its fiscal Q4 2026 total revenue guidance to $1.057 - $1.080 billion (0% to 2% organic growth) and its full-year fiscal 2026 revenue guidance to $4.229 - $4.252 billion (2% to 3% organic growth). Non-GAAP diluted EPS guidance was also lowered for fiscal Q4 2026 to $1.05 - $1.09 and for the full fiscal year 2026 to $4.51 - $4.55. This guidance cut contributed to a 15% stock plunge on September 10, 2026.
2. The company unexpectedly decided to retain its CooperSurgical business following a strategic review. After undertaking a strategic review process since December 2025, CooperCompanies announced on September 9, 2026, that its board decided against the potential sale of its CooperSurgical division. The board concluded that retaining the business was the best course for maximizing shareholder value at the time. This decision surprised analysts who had anticipated a sale, leading several firms, including William Blair, BofA Securities, Wells Fargo, and Piper Sandler, to downgrade the stock and reduce their price targets.
3. A significant leadership transition occurred amid stated underperformance, indicating operational challenges. On October 27, 2026, CooperCompanies announced that President and Chief Executive Officer Albert White III stepped down, with independent director Walter M. Rosebrough, Jr. elected Executive Chair during the search for a permanent CEO. The company's board explicitly stated that "recent performance has not met our expectations" and that "decisive action is needed to ensure the Company reaches its long-term potential," highlighting dissatisfaction with the company's operational execution and overall business performance.
4. The broader medical device sector experienced underperformance. Throughout 2026, the medical device sector underperformed the broader markets. In August 2026, the sector saw stock prices "getting hammered" despite growing revenues for some companies, suggesting that the market was anticipating problems not yet reflected in earnings reports. An October 19, 2026, report by EY noted persistent negative investor sentiment and ongoing global trade and supply chain uncertainties affecting the MedTech industry.
Show less
Stock Movement Drivers
Fundamental Drivers
The -12.2% change in COO stock from 7/31/2026 to 11/5/2026 was primarily driven by a -64.1% change in the company's P/E Multiple.| (LTM values as of) | 7312026 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 72.32 | 63.51 | -12.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4,231 | 4,237 | 0.1% |
| Net Income Margin (%) | 5.6% | 13.5% | 141.5% |
| P/E Multiple | 59.8 | 21.5 | -64.1% |
| Shares Outstanding (Mil) | 195 | 193 | 1.0% |
| Cumulative Contribution | -12.2% |
Market Drivers
7/31/2026 to 11/5/2026| Return | Correlation | |
|---|---|---|
| COO | -12.2% | |
| Market (SPY) | -1.9% | 13.8% |
| Sector (XLV) | 13.8% | 38.2% |
Fundamental Drivers
The 1.0% change in COO stock from 4/30/2026 to 11/5/2026 was primarily driven by a 39.2% change in the company's Net Income Margin (%).| (LTM values as of) | 4302026 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 62.90 | 63.51 | 1.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4,152 | 4,237 | 2.0% |
| Net Income Margin (%) | 9.7% | 13.5% | 39.2% |
| P/E Multiple | 30.7 | 21.5 | -29.9% |
| Shares Outstanding (Mil) | 196 | 193 | 1.5% |
| Cumulative Contribution | 1.0% |
Market Drivers
4/30/2026 to 11/5/2026| Return | Correlation | |
|---|---|---|
| COO | 1.0% | |
| Market (SPY) | 2.3% | 0.6% |
| Sector (XLV) | 27.2% | 44.5% |
Fundamental Drivers
The -9.2% change in COO stock from 10/31/2025 to 11/5/2026 was primarily driven by a -37.1% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 69.91 | 63.51 | -9.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4,046 | 4,237 | 4.7% |
| Net Income Margin (%) | 10.1% | 13.5% | 33.5% |
| P/E Multiple | 34.2 | 21.5 | -37.1% |
| Shares Outstanding (Mil) | 199 | 193 | 3.3% |
| Cumulative Contribution | -9.2% |
Market Drivers
10/31/2025 to 11/5/2026| Return | Correlation | |
|---|---|---|
| COO | -9.2% | |
| Market (SPY) | 8.4% | 19.8% |
| Sector (XLV) | 29.8% | 49.1% |
Fundamental Drivers
The -18.5% change in COO stock from 10/31/2023 to 11/5/2026 was primarily driven by a -61.7% change in the company's P/E Multiple.| (LTM values as of) | 10312023 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 77.94 | 63.51 | -18.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,514 | 4,237 | 20.6% |
| Net Income Margin (%) | 7.8% | 13.5% | 71.8% |
| P/E Multiple | 56.1 | 21.5 | -61.7% |
| Shares Outstanding (Mil) | 198 | 193 | 2.6% |
| Cumulative Contribution | -18.5% |
Market Drivers
10/31/2023 to 11/5/2026| Return | Correlation | |
|---|---|---|
| COO | -18.5% | |
| Market (SPY) | 81.3% | 33.6% |
| Sector (XLV) | 55.5% | 48.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| COO Return | 15% | -21% | 14% | -3% | -11% | -23% | -30% |
| Peers Return | 7% | -8% | 9% | 14% | 18% | 2% | 48% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 105% |
Monthly Win Rates [3] | |||||||
| COO Win Rate | 67% | 50% | 58% | 50% | 50% | 45% | |
| Peers Win Rate | 47% | 52% | 50% | 56% | 65% | 45% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 45% | |
Max Drawdowns [4] | |||||||
| COO Max Drawdown | -18% | -42% | -23% | -18% | -35% | -37% | |
| Peers Max Drawdown | -18% | -23% | -20% | -14% | -20% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: JNJ, BSX, BLCO, MDT. See COO Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/5/2026 (YTD)
How Low Can It Go
| Event | COO | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -20.6% | -9.5% |
| % Gain to Breakeven | 25.9% | 10.5% |
| Time to Breakeven | 84 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -41.0% | -24.5% |
| % Gain to Breakeven | 69.5% | 32.4% |
| Time to Breakeven | 685 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -31.7% | -33.7% |
| % Gain to Breakeven | 46.5% | 50.9% |
| Time to Breakeven | 200 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.7% | -19.2% |
| % Gain to Breakeven | 18.6% | 23.8% |
| Time to Breakeven | 37 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -10.8% | -3.7% |
| % Gain to Breakeven | 12.2% | 3.9% |
| Time to Breakeven | 40 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -30.5% | -12.2% |
| % Gain to Breakeven | 43.8% | 13.9% |
| Time to Breakeven | 164 days | 62 days |
In The Past
Cooper Companies's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | COO | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -20.6% | -9.5% |
| % Gain to Breakeven | 25.9% | 10.5% |
| Time to Breakeven | 84 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -41.0% | -24.5% |
| % Gain to Breakeven | 69.5% | 32.4% |
| Time to Breakeven | 685 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -31.7% | -33.7% |
| % Gain to Breakeven | 46.5% | 50.9% |
| Time to Breakeven | 200 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -30.5% | -12.2% |
| % Gain to Breakeven | 43.8% | 13.9% |
| Time to Breakeven | 164 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -25.7% | -6.8% |
| % Gain to Breakeven | 34.7% | 7.3% |
| Time to Breakeven | 126 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -20.7% | -17.9% |
| % Gain to Breakeven | 26.1% | 21.8% |
| Time to Breakeven | 43 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -70.8% | -53.4% |
| % Gain to Breakeven | 242.1% | 114.4% |
| Time to Breakeven | 389 days | 1085 days |
In The Past
Cooper Companies's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Cooper Companies (COO)
The Cooper Companies (COO) is a global medical device company primarily operating in two distinct segments: vision care and women's healthcare. Founded in 1958, the company manufactures and markets a wide range of products designed to improve health and quality of life for its diverse customer base worldwide.
Its CooperVision segment is a leading provider of contact lenses. This division offers an extensive portfolio of lenses, including standard spherical lenses for correcting common near and farsightedness, as well as specialized toric lenses for astigmatism and multifocal lenses addressing presbyopia, myopia, ocular dryness, and eye fatigue. These vision correction solutions serve contact lens wearers across the Americas, Europe, Middle East, Africa, and Asia Pacific regions.
The second key segment, CooperSurgical, focuses on family and women's health. This segment supplies healthcare professionals and patients globally with a broad array of medical devices, fertility solutions, and diagnostic products. Its offerings include surgical and office products like uterine manipulators and the PARAGARD IUD, alongside comprehensive fertility products and services such as consumables, equipment, embryo options, and preimplantation genetic testing.
```AI Analysis | Feedback
Imagine a company that's essentially the contact lens business of an Alcon or the vision care division of Johnson & Johnson, combined with a women's health medical device and fertility company like Hologic.
AI Analysis | Feedback
- Spherical Lenses: Contact lenses that correct common vision impairments such as near and farsightedness.
- Toric and Multifocal Lenses: Specialized contact lenses designed to correct vision challenges including astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues.
- Surgical and Office Medical Devices: A range of products for women's healthcare, including uterine manipulators, retractors, closure products, LEEP products, endosee, illuminate, and fetal pillows.
- PARAGARD: A specific product provided for contraception.
- Fertility Products and Services: Offerings include fertility consumables, equipment, embryo options, and preimplantation genetic testing for reproductive health.
- Genomics and Diagnostics Services: Provide advanced testing and diagnostic solutions for family and women's health.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Albert G. White III, President & Chief Executive Officer
Albert G. White III has served as President & Chief Executive Officer of The Cooper Companies since May 2018. Prior to this role, he was Chief Financial Officer from November 2016. He also held positions as Executive Vice President and Chief Strategy Officer. From August 2015 to May 2018, Mr. White directed Cooper's women's healthcare business and served as Chief Executive Officer of Cooper Medical Inc., which is the parent company to CooperSurgical. Before joining Cooper in 2006, he was a Director with KeyBanc Capital Markets for three years and held various leadership roles within KeyBank National Association for eight years. Mr. White currently serves as a board member of Evolvus Inc.
Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer
Brian Andrews was promoted to Senior Vice President, Chief Financial Officer and Treasurer of The Cooper Companies in May 2018. He assumed the additional role of principal accounting officer in December 2025. Mr. Andrews began his career at Cooper in 2006 as Assistant Treasurer, later serving as Treasurer and Vice President. In 2017, he added the role of Vice President, Global Logistics and Service for CooperSurgical. Before joining Cooper, he held various corporate and investment banking positions at KeyBanc Capital Markets and ING Barings.
Daniel G. McBride, Executive Vice President & Chief Operating Officer
Daniel G. McBride has served as Executive Vice President and Chief Operating Officer of The Cooper Companies since November 2013. His previous roles at Cooper include President of CooperVision from 2014 to 2022, Chief Risk Officer, General Counsel, and Senior Counsel. Before joining Cooper in February 2005, Mr. McBride was an attorney with Latham & Watkins LLP, where he focused on mergers and acquisitions and corporate finance matters.
Jerry Warner, President of CooperVision
Jerry Warner is the President of CooperVision. He is also listed as an insider who has purchased shares of Cooper Companies stock.
Holly Sheffield, President of CooperSurgical
Holly Sheffield serves as the President of CooperSurgical. Insider trading records indicate she has purchased shares of Cooper Companies stock.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
The Cooper Companies, Inc. (symbol: COO) operates in two main segments: CooperVision, focusing on contact lenses, and CooperSurgical, dedicated to family and women's healthcare. The addressable markets for their main products and services are as follows:
CooperVision Segment
- Contact Lenses (overall market including spherical, toric, and multifocal lenses): The global contact lenses market was estimated at approximately $20.24 billion USD in 2024 and is projected to reach about $33.80 billion USD by 2030.
- Toric Lenses (for astigmatism correction): The global astigmatism contact lens market is projected to reach $8.733 billion USD in 2025 and is expected to grow to over $16 billion USD by 2033.
- Multifocal Lenses (for presbyopia correction): The global multifocal contact lenses market size was valued at $3.45 billion USD in 2025 and is projected to grow to $5.89 billion USD by 2034.
- Myopia Treatment (including lenses for myopia control): The global myopia treatment market was valued at approximately $18 billion USD in 2023 and is expected to reach $41 billion USD by the end of 2032.
- Dry Eye Disease (treatment, including related contact lenses for ocular dryness and eye fatigues): The global dry eye disease market size was valued at $6.43 billion USD in 2024 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.04% from 2025 to 2034.
CooperSurgical Segment
- Gynecology Surgical Instruments (a proxy for women's health medical devices): The global gynecology surgical instruments market accrued earnings of approximately $9.95 billion USD in 2023 and is predicted to reach about $20.11 billion USD by 2032.
- Fertility Products and Services: The global fertility services market was valued at $51.9 billion USD in 2025 and is estimated to reach $150.2 billion USD by 2034.
- Preimplantation Genetic Testing (PGT, part of genomics/diagnostics): The global preimplantation genetic testing market size was valued at $928.78 billion USD in 2025 and is projected to grow to $1736.79 billion USD by 2034.
- Intrauterine Devices (IUDs, for contraception, e.g., PARAGARD): The global intrauterine devices market was valued at $4 billion USD in 2024 and is expected to grow to $11 billion USD by 2034.
- Uterine Manipulators (surgical and office products): The global uterine manipulation devices market was valued at $367 million USD in 2024 and is expected to grow to $610.7 million USD by 2034.
AI Analysis | Feedback
AI Analysis | Feedback
Share Repurchases
- In September 2025, CooperCompanies increased its share repurchase program by $1 billion, bringing the total authorization to $2 billion. This program has no specified termination date and can be adjusted or discontinued at any time.
- The company reported $92.5 million in share repurchases during its first quarter of fiscal year 2026, which ended January 31, 2026.
- The expanded repurchase program is part of CooperCompanies' disciplined capital allocation strategy, which balances investments and debt reduction with returning capital to shareholders.
Share Issuance
- On February 20, 2024, Cooper Companies underwent a 4:1 forward stock split.
Outbound Investments
- Cooper Companies made 4 acquisitions in 2021.
- The most significant recent acquisition was Generate, a provider of stem cell storage services, acquired in November 2021 for $1.6 billion.
- Other acquisitions in 2021 included OBP Medical, Safe Obstetric Systems, and SightGlass Vision, though their specific financial details were not disclosed.
Capital Expenditures
- Capital expenditures for the last twelve months (LTM) as of October 28, 2025, amounted to $83 million.
- In the first quarter of fiscal year 2026, capital spending was $102.2 million.
- Projected capital expenditures for fiscal year 2026 are estimated to be $388 million, primarily focused on maintaining existing assets and expanding property, plant, and equipment.
Peer Outperformance in Health Care Supplies
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| COO | Cooper Companies | 6.4% | 21.5x | -7.8% | -24.1% | -40.1% | — |
| HAE | Haemonetics | 3.8% | 54.3x | 144.7% | 40.3% | 66.4% | +106pp |
| MMSI | Merit Medical Systems | 9.5% | 33.5x | 2.9% | 26.0% | 29.0% | +69pp |
| WST | West Pharmaceutical Services | 5.3% | 43.2x | 38.9% | 18.8% | -1.6% | +39pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 7.6% | 56.6% | 93.6% | CAH 498% · MCK 396% · COR 181% |
| Health Care Services | 20 | 33.8% | 28.8% | 6.1% | HIMS 189% · RDNT 125% · DGX 100% |
| Health Care Facilities | 25 | 13.9% | 27.4% | -1.4% | THC 280% · NHC 210% · EHC 186% |
| Managed Health Care | 8 | 47.9% | 1.6% | -2.2% | OSCR 95% · HQY 52% · ELV 10% |
| Health Care Equipment | 50 | 11.0% | 17.8% | -17.6% | UFPT 355% · GKOS 286% · PLSE 127% |
| Pharmaceuticals | 61 | -12.9% | 10.6% | -37.3% | LQDA 977% · XERS 571% · KNSA 500% |
| Health Care Supplies ← | 11 | 23.9% | 17.0% | -40.1% | LNTH 248% · HAE 66% · MMSI 29% |
| Life Sciences Tools & Services | 108 | -8.1% | -18.9% | -74.5% | AXGN 255% · NTRA 214% · MEDP 181% |
| Biotechnology | 364 | -25.8% | -36.1% | -82.0% | ELVN 1073% · TRVI 995% · DNTH 956% |
| Health Care Technology | 21 | -21.4% | -50.4% | -82.8% | VEEV -3% · DOCS -51% |
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 63.49 |
| Mkt Cap | 64.3 |
| Rev LTM | 21,069 |
| Op Inc LTM | 4,338 |
| FCF LTM | 1,516 |
| FCF 3Y Avg | 2,325 |
| CFO LTM | 4,234 |
| CFO 3Y Avg | 3,932 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.9% |
| Rev Chg 3Y Avg | 6.4% |
| Rev Chg Q | 5.9% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Inc Chg LTM | 7.9% |
| Op Inc Chg 3Y Avg | 6.3% |
| Op Mgn LTM | 19.0% |
| Op Mgn 3Y Avg | 18.5% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 21.4% |
| CFO/Rev 3Y Avg | 20.8% |
| FCF/Rev LTM | 16.0% |
| FCF/Rev 3Y Avg | 12.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 64.3 |
| P/S | 3.1 |
| P/Op Inc | 18.8 |
| P/EBIT | 18.8 |
| P/E | 21.5 |
| P/CFO | 15.2 |
| Total Yield | 4.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.4% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 12.5% |
| 3M Rtn | 6.0% |
| 6M Rtn | 23.1% |
| 12M Rtn | 19.8% |
| 3Y Rtn | 20.1% |
| 1M Excs Rtn | 16.5% |
| 3M Excs Rtn | 5.9% |
| 6M Excs Rtn | 18.3% |
| 12M Excs Rtn | 6.2% |
| 3Y Excs Rtn | -59.9% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| CooperVision | 2,744 | 2,609 | 2,424 | 2,243 | 2,152 |
| CooperSurgical | 1,349 | 1,286 | 1,170 | 1,065 | 770 |
| Corporate | 0 | 0 | 0 | 0 | 0 |
| Total | 4,092 | 3,895 | 3,593 | 3,308 | 2,922 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| CooperVision | 730 | 676 | 588 | 494 | 481 |
| CooperSurgical | 43 | 118 | 16 | 67 | 72 |
| Corporate | -90 | -89 | -71 | -54 | -47 |
| Total | 683 | 706 | 533 | 508 | 506 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| CooperVision | 7,604 | 7,285 | 7,044 | 6,779 | 6,966 |
| CooperSurgical | 4,619 | 4,832 | 4,352 | 4,408 | 2,396 |
| Corporate | 171 | 198 | 263 | 306 | 245 |
| Total | 12,395 | 12,315 | 11,659 | 11,492 | 9,606 |
Price Behavior
| Market Price | $63.51 | |
| Market Cap ($ Bil) | 12.3 | |
| First Trading Date | 12/30/1983 | |
| Distance from 52W High | -24.7% | |
| 50 Days | 200 Days | |
| DMA Price | $59.37 | $68.51 |
| DMA Trend | down | down |
| Distance from DMA | 7.0% | -7.3% |
| 3M | 1YR | |
| Volatility | 43.2% | 32.5% |
| Downside Capture | 105.21 | 68.38 |
| Upside Capture | 22.96 | 49.73 |
| Correlation (S&P 500) | 8.8% | 19.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.38 | 0.13 | 0.27 | -0.17 | 0.45 | 0.69 |
| Up Beta | -5.83 | -2.54 | -0.27 | -0.22 | 0.56 | 0.91 |
| Down Beta | -0.82 | -0.19 | 0.10 | -0.79 | 0.04 | 0.45 |
| Up Capture | 54% | 8% | -0% | 2% | 33% | 22% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 10 | 19 | 29 | 58 | 110 | 360 |
| Down Capture | -30% | 131% | 115% | 19% | 79% | 93% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 12 | 23 | 34 | 67 | 140 | 388 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COO | |
|---|---|---|---|---|
| COO | -8.1% | 32.5% | -0.23 | - |
| Sector ETF (XLV) | 29.2% | 16.9% | 1.33 | 49.2% |
| Equity (SPY) | 9.5% | 13.6% | 0.41 | 19.6% |
| Gold (GLD) | 3.6% | 28.7% | 0.11 | 8.7% |
| Commodities (DBC) | 37.7% | 21.2% | 1.40 | -28.0% |
| Real Estate (VNQ) | 12.0% | 14.2% | 0.55 | 42.3% |
| Bitcoin (BTCUSD) | -20.8% | 43.3% | -0.42 | 4.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COO | |
|---|---|---|---|---|
| COO | -9.4% | 30.5% | -0.30 | - |
| Sector ETF (XLV) | 8.6% | 15.4% | 0.36 | 54.7% |
| Equity (SPY) | 11.3% | 17.3% | 0.48 | 48.0% |
| Gold (GLD) | 17.5% | 19.1% | 0.74 | 14.5% |
| Commodities (DBC) | 8.0% | 19.6% | 0.29 | 1.5% |
| Real Estate (VNQ) | 1.2% | 18.9% | -0.05 | 52.4% |
| Bitcoin (BTCUSD) | 5.9% | 51.5% | 0.29 | 21.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COO | |
|---|---|---|---|---|
| COO | 3.7% | 28.7% | 0.17 | - |
| Sector ETF (XLV) | 12.2% | 16.8% | 0.60 | 58.9% |
| Equity (SPY) | 14.9% | 18.0% | 0.70 | 54.6% |
| Gold (GLD) | 12.0% | 16.5% | 0.59 | 10.3% |
| Commodities (DBC) | 7.6% | 18.1% | 0.33 | 10.5% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.23 | 51.1% |
| Bitcoin (BTCUSD) | 61.3% | 66.2% | 1.01 | 16.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 10/12/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 9/9/2026 | -14.7% | -14.0% | -14.5% |
| 6/4/2026 | 8.6% | 8.9% | 15.9% |
| 3/5/2026 | -4.6% | -10.8% | -12.4% |
| 12/4/2025 | 5.7% | 6.6% | 8.9% |
| 8/27/2025 | -12.9% | -8.2% | -8.8% |
| 5/29/2025 | -14.6% | -11.0% | -11.0% |
| 3/6/2025 | -6.6% | -14.6% | -18.9% |
| 12/5/2024 | -4.4% | -6.3% | -10.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 13 | 13 |
| # Negative | 12 | 11 | 11 |
| Median Positive | 4.5% | 6.5% | 7.6% |
| Median Negative | -4.5% | -7.6% | -10.5% |
| Max Positive | 11.8% | 12.7% | 16.1% |
| Max Negative | -14.7% | -14.6% | -18.9% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 9/9/2026 | -14.7% | -14.0% | -14.5% |
| 6/4/2026 | 8.6% | 8.9% | 15.9% |
| 3/5/2026 | -4.6% | -10.8% | -12.4% |
| 12/4/2025 | 5.7% | 6.6% | 8.9% |
| 8/27/2025 | -12.9% | -8.2% | -8.8% |
| 5/29/2025 | -14.6% | -11.0% | -11.0% |
| 3/6/2025 | -6.6% | -14.6% | -18.9% |
| 12/5/2024 | -4.4% | -6.3% | -10.2% |
| 8/28/2024 | 11.8% | 12.7% | 16.1% |
| 5/30/2024 | 4.5% | 5.6% | -4.3% |
| 2/29/2024 | 9.2% | 9.1% | 6.0% |
| 12/7/2023 | -2.9% | 6.5% | 7.6% |
| 8/30/2023 | -2.9% | -7.1% | -16.5% |
| 6/1/2023 | -4.7% | -6.5% | 0.9% |
| 3/2/2023 | 7.3% | 2.1% | 13.9% |
| 12/8/2022 | -3.1% | 1.5% | 7.6% |
| 8/31/2022 | 4.4% | 7.1% | -8.2% |
| 6/2/2022 | -3.0% | -4.5% | -10.5% |
| 3/3/2022 | 1.8% | -7.6% | 2.7% |
| 12/2/2021 | 3.6% | 8.1% | 11.5% |
| 9/2/2021 | 1.2% | 0.2% | -9.3% |
| 6/3/2021 | -0.6% | -2.6% | 6.2% |
| 3/4/2021 | 4.5% | 2.2% | 4.4% |
| 12/3/2020 | 2.3% | 2.9% | 7.0% |
| SUMMARY STATS | |||
| # Positive | 12 | 13 | 13 |
| # Negative | 12 | 11 | 11 |
| Median Positive | 4.5% | 6.5% | 7.6% |
| Median Negative | -4.5% | -7.6% | -10.5% |
| Max Positive | 11.8% | 12.7% | 16.1% |
| Max Negative | -14.7% | -14.6% | -18.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 07/31/2026 | 09/09/2026 | 10-Q |
| 04/30/2026 | 06/05/2026 | 10-Q |
| 01/31/2026 | 03/06/2026 | 10-Q |
| 10/31/2025 | 12/05/2025 | 10-K |
| 07/31/2025 | 08/28/2025 | 10-Q |
| 04/30/2025 | 05/30/2025 | 10-Q |
| 01/31/2025 | 03/07/2025 | 10-Q |
| 10/31/2024 | 12/06/2024 | 10-K |
| 07/31/2024 | 08/29/2024 | 10-Q |
| 04/30/2024 | 05/31/2024 | 10-Q |
| 01/31/2024 | 03/01/2024 | 10-Q |
| 10/31/2023 | 12/08/2023 | 10-K |
| 07/31/2023 | 08/31/2023 | 10-Q |
| 04/30/2023 | 06/02/2023 | 10-Q |
| 01/31/2023 | 03/03/2023 | 10-Q |
| 10/31/2022 | 12/09/2022 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 07/31/2026 | 09/09/2026 | 10-Q |
| 04/30/2026 | 06/05/2026 | 10-Q |
| 01/31/2026 | 03/06/2026 | 10-Q |
| 10/31/2025 | 12/05/2025 | 10-K |
| 07/31/2025 | 08/28/2025 | 10-Q |
| 04/30/2025 | 05/30/2025 | 10-Q |
| 01/31/2025 | 03/07/2025 | 10-Q |
| 10/31/2024 | 12/06/2024 | 10-K |
| 07/31/2024 | 08/29/2024 | 10-Q |
| 04/30/2024 | 05/31/2024 | 10-Q |
| 01/31/2024 | 03/01/2024 | 10-Q |
| 10/31/2023 | 12/08/2023 | 10-K |
| 07/31/2023 | 08/31/2023 | 10-Q |
| 04/30/2023 | 06/02/2023 | 10-Q |
| 01/31/2023 | 03/03/2023 | 10-Q |
| 10/31/2022 | 12/09/2022 | 10-K |
| 07/31/2022 | 09/01/2022 | 10-Q |
| 04/30/2022 | 06/03/2022 | 10-Q |
| 01/31/2022 | 03/04/2022 | 10-Q |
| 10/31/2021 | 12/10/2021 | 10-K |
| 07/31/2021 | 09/03/2021 | 10-Q |
| 04/30/2021 | 06/04/2021 | 10-Q |
| 01/31/2021 | 03/05/2021 | 10-Q |
| 10/31/2020 | 12/11/2020 | 10-K |
| 07/31/2020 | 09/04/2020 | 10-Q |
| 04/30/2020 | 06/05/2020 | 10-Q |
| 01/31/2020 | 03/06/2020 | 10-Q |
| 10/31/2019 | 12/20/2019 | 10-K |
Recent Forward Guidance
Updated 9/10/2026Latest: Q3 2026 Earnings Reported 9/9/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2026 Revenue | Reported | 1.06 Bil | 1.07 Bil | 1.08 Bil | ||||
| Q4 2026 Organic Revenue Growth | Reported | 0.0% | 1.0% | 2.0% | ||||
| Q4 2026 CVI Revenue | Reported | 692.00 Mil | 699.00 Mil | 706.00 Mil | ||||
| Q4 2026 CVI Organic Revenue Growth | Reported | -2.0% | -1.0% | 0.0% | ||||
| Q4 2026 CSI Revenue | Reported | 364.00 Mil | 369.00 Mil | 374.00 Mil | ||||
| Q4 2026 CSI Organic Revenue Growth | Reported | 4.0% | 5.0% | 6.0% | ||||
| Q4 2026 Non-GAAP Diluted EPS | Reported | 1.05 | 1.07 | 1.09 | ||||
| 2026 Revenue | Reported | 4.23 Bil | 4.24 Bil | 4.25 Bil | -1.5% | Lowered | Guidance: 4.30 Bil for 2026 | |
| 2026 Organic Revenue Growth | Reported | 2.0% | 2.5% | 3.0% | -1.5% | Lowered | Guidance: 4.0% for 2026 | |
| 2026 CVI Revenue | Reported | 2.83 Bil | 2.83 Bil | 2.84 Bil | -2.1% | Lowered | Guidance: 2.90 Bil for 2026 | |
| 2026 CVI Organic Revenue Growth | Reported | 1.0% | 1.5% | 2.0% | -2.5% | Lowered | Guidance: 4.0% for 2026 | |
| 2026 CSI Revenue | Reported | 1.40 Bil | 1.41 Bil | 1.41 Bil | -0.2% | Lowered | Guidance: 1.41 Bil for 2026 | |
| 2026 CSI Organic Revenue Growth | Reported | 4.0% | 4.5% | 5.0% | 0.0% | Affirmed | Guidance: 4.5% for 2026 | |
| 2026 Non-GAAP Diluted EPS | Reported | 4.51 | 4.53 | 4.55 | -1.9% | Lowered | Guidance: 4.62 for 2026 | |
Prior: Q2 2026 Earnings Reported 6/4/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenue | Reported | 4.29 Bil | 4.30 Bil | 4.32 Bil | -0.5% | Lowered | Guidance: 4.33 Bil for 2026 | |
| 2026 Total Revenue Organic Growth | Reported | 3.5% | 4.0% | 4.5% | ||||
| 2026 CVI Revenue | Reported | 2.88 Bil | 2.90 Bil | 2.91 Bil | -0.8% | Lowered | Guidance: 2.92 Bil for 2026 | |
| 2026 CVI Revenue Organic Growth | Reported | 3.5% | 4.0% | 4.5% | ||||
| 2026 CSI Revenue | Reported | 1.40 Bil | 1.41 Bil | 1.41 Bil | 0.1% | Raised | Guidance: 1.41 Bil for 2026 | |
| 2026 CSI Revenue Organic Growth | Reported | 4.0% | 4.5% | 5.0% | ||||
| 2026 Non-GAAP Diluted EPS | Reported | 4.58 | 4.62 | 4.66 | 0 | Affirmed | Guidance: 4.62 for 2026 | |
| 2026 Free Cash Flow | Reported | 2.20 Bil | 259.2% | Affirmed | Guidance: 612.50 Mil for 2026 | |||
Q1 2026 Earnings Reported 3/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenue | Reported | 4.31 Bil | 4.33 Bil | 4.35 Bil | 0.2% | Raised | Guidance: 4.32 Bil for 2026 | |
| 2026 CVI Revenue | Reported | 2.91 Bil | 2.92 Bil | 2.93 Bil | 0.2% | Raised | Guidance: 2.91 Bil for 2026 | |
| 2026 CSI Revenue | Reported | 1.40 Bil | 1.41 Bil | 1.41 Bil | 0.0% | Raised | Guidance: 1.41 Bil for 2026 | |
| 2026 Non-GAAP Diluted EPS | Reported | 4.58 | 4.62 | 4.66 | 2.1% | Raised | Guidance: 4.53 for 2026 | |
| 2026 Free Cash Flow | Reported | 600.00 Mil | 612.50 Mil | 625.00 Mil | 2.1% | Raised | Guidance: 600.00 Mil for 2026 | |
Q4 2025 Earnings Reported 12/4/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue | Reported | 1.02 Bil | 1.02 Bil | 1.03 Bil | ||||
| Q1 2026 CVI Revenue | Reported | 693.00 Mil | 696.50 Mil | 700.00 Mil | ||||
| Q1 2026 CSI Revenue | Reported | 327.00 Mil | 328.50 Mil | 330.00 Mil | ||||
| Q1 2026 Non-GAAP Diluted EPS | Reported | 1.02 | 1.03 | 1.04 | ||||
| 2026 Revenue | Reported | 4.30 Bil | 4.32 Bil | 4.34 Bil | 5.7% | Higher New | Actual: 4.09 Bil for 2025 | |
| 2026 CVI Revenue | Reported | 2.90 Bil | 2.91 Bil | 2.92 Bil | 6.3% | Higher New | Actual: 2.74 Bil for 2025 | |
| 2026 CSI Revenue | Reported | 1.40 Bil | 1.41 Bil | 1.41 Bil | 4.5% | Higher New | Actual: 1.35 Bil for 2025 | |
| 2026 Non-GAAP Diluted EPS | Reported | 4.45 | 4.53 | 4.6 | 10.4% | Higher New | Actual: 4.1 for 2025 | |
| 2026 Free Cash Flow | Reported | 575.00 Mil | 600.00 Mil | 625.00 Mil | ||||
Insider Activity
Updated 9/17/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kurzius, Lawrence Erik | Direct | Buy | 9172026 | 54.93 | 10,000 | 549,320 | 1,708,330 | Form | |
| 2 | Rosebrough, Walter M JR | see footnote | Buy | 9152026 | 54.29 | 3,000 | 162,870 | 1,085,800 | Form | |
| 3 | Kurzius, Lawrence Erik | Direct | Buy | 9152026 | 53.91 | 10,000 | 539,150 | 1,137,553 | Form | |
| 4 | Rosebrough, Walter M JR | see footnote | Buy | 9152026 | 54.11 | 7,000 | 378,770 | 919,870 | Form | |
| 5 | Keel, Paul A | Direct | Buy | 9152026 | 53.18 | 4,701 | 250,000 | 250,000 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kurzius, Lawrence Erik | Direct | Buy | 9172026 | 54.93 | 10,000 | 549,320 | 1,708,330 | Form | |
| 2 | Rosebrough, Walter M JR | see footnote | Buy | 9152026 | 54.29 | 3,000 | 162,870 | 1,085,800 | Form | |
| 3 | Kurzius, Lawrence Erik | Direct | Buy | 9152026 | 53.91 | 10,000 | 539,150 | 1,137,553 | Form | |
| 4 | Rosebrough, Walter M JR | see footnote | Buy | 9152026 | 54.11 | 7,000 | 378,770 | 919,870 | Form | |
| 5 | Keel, Paul A | Direct | Buy | 9152026 | 53.18 | 4,701 | 250,000 | 250,000 | Form | |
| 6 | Lucchese, Cynthia L | Direct | Buy | 12232025 | 84.06 | 1,784 | 149,963 | 793,947 | Form | |
| 7 | Rivas, Maria | see footnote | Buy | 12192025 | 82.13 | 1,000 | 82,130 | 915,010 | Form | |
| 8 | Kurzius, Lawrence Erik | Direct | Buy | 12172025 | 82.50 | 2,000 | 165,000 | 641,602 | Form | |
| 9 | Sheffield, Holly R | President, CSI | Direct | Buy | 12162025 | 80.75 | 1,230 | 99,322 | 3,153,449 | Form |
| 10 | White, Albert G Iii | President & CEO | Direct | Buy | 12162025 | 80.80 | 10,000 | 808,000 | 19,081,001 | Form |
| 11 | Kurzius, Lawrence Erik | Direct | Buy | 9292025 | 68.39 | 2,000 | 136,780 | 395,089 | Form | |
| 12 | White, Albert G Iii | President & CEO | Direct | Buy | 9052025 | 68.39 | 10,000 | 683,900 | 15,466,467 | Form |
| 13 | Warner, Gerard H Iii | President, CooperVision, Inc. | Direct | Buy | 9052025 | 69.23 | 1,450 | 100,384 | 1,268,224 | Form |
| 14 | McBride, Daniel G | EVP & Chief Operating Officer | Direct | Buy | 9022025 | 65.04 | 3,000 | 195,120 | 4,105,325 | Form |
| 15 | Andrews, Brian G | EVP, CFO & Treasurer | See footnote | Buy | 9022025 | 65.68 | 1,525 | 100,162 | 1,457,505 | Form |
Investor Activity (13F)
Updated Nov 6, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Browning West LP | $499.0 Mil | 30.9% | 5 | ADD +89.1% | 13F |
| JANA Partners Management, LP | $254.9 Mil | 15.9% | 10 | Hold | 13F |
| Longview Partners (Guernsey) LTD | $273.3 Mil | 3.9% | 25 | New | 13F |
| Generation Investment Management LLP | $328.9 Mil | 2.9% | 29 | ADD +61.4% | 13F |
| Triodos Investment Management BV | $17.7 Mil | 1.3% | 49 | Hold | 13F |
| Goodnow Investment Group, LLC | $8.4 Mil | 0.9% | 29 | New | 13F |
| Active Manager | Value | % of Portfolio | Total Positions | QoQ | Filing |
|---|---|---|---|---|---|
| Browning West LP | $499.0 Mil | 30.9% | 5 | ADD +89.1% | 13F |
| Generation Investment Management LLP | $328.9 Mil | 2.9% | 29 | ADD +61.4% | 13F |
| Longview Partners (Guernsey) LTD | $273.3 Mil | 3.9% | 25 | New | 13F |
| JANA Partners Management, LP | $254.9 Mil | 15.9% | 10 | Hold | 13F |
| Triodos Investment Management BV | $17.7 Mil | 1.3% | 49 | Hold | 13F |
| Goodnow Investment Group, LLC | $8.4 Mil | 0.9% | 29 | New | 13F |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.

